Biological systems involved in disease are inherently complex and targeting a single receptor/ligand interaction or an individual pathway employing monotherapy often does not mediate maximal therapeutic benefit. Cancer immunotherapy results have shown that a combination of two separate antibodies can produce improved clinical outcomes as compared to monotherapy. There is a pressing medical need to develop technology that enables interdiction of multiple pathways by efficiently producing a single drug product that contains more that one therapeutic antibody.
Sound Biologics is building a new technology platform to produce the next generation of therapeutic antibodies that are capable of targeting multiple molecules and pathways. Our proprietary MabPair™ platform enables the development of custom-designed antibody combinations that bring the synergy of a two full-antibody combination and reduce the opportunity for tumor escape and drug resistance. The MabPair™ platform also offers the advantages regarding convenience of administration and reduced cost when compared to conventional antibody combination therapies.
Innovation
Scanning electron micrograph of T cells attacking a tumor cell.
Discovery engine
- Target validation and assay development
- lead discovery and screening
- In vivo models
Antibody platform
- Lead discovery and optimization by yeast display
- MabPair™ and Ab cocktail
- Enhanced antibodies on PK, bioavailability and effector functions
Process development
- Host cells and vectors
- Stable cell line development
- Upstream process
- Downstream process
- Analytical and CMC team